SEC Form 4 · accession 0001053369-15-000011
ELITE PHARMACEUTICALS INC /NV/ · ELTP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ashok G Nigalaye
Director · 10% Owner
Period of report
Apr 3, 2015
Accepted (ET)
Apr 7, 2015 · 9:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001053369
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF2 | $0.0625 | Apr 3, 2015 | J | 2,454,665 | D | Jun 3, 2009 | Jun 3, 2016 | Common Stock | 2,454,665 | 0 | I |
| WarrantsF2 | $0.0625 | Apr 3, 2015 | J | 6,726,999 | D | Oct 30, 2009 | Oct 30, 2016 | Common Stock | 6,726,999 | 0 | I |
| WarrantsF2 | $0.0625 | Apr 3, 2015 | J | 40,000,000 | D | Mar 31, 2011 | Mar 31, 2018 | Common Stock | 40,000,000 | 0 | I |
| WarrantsF2 | $0.0625 | Apr 3, 2015 | J | 4,000,000 | D | Apr 25, 2011 | Apr 25, 2018 | Common Stock | 4,000,000 | 0 | I |
| WarrantsF3 | $0.0625 | Apr 3, 2015 | J | 2,454,665 | A | Jun 3, 2009 | Jun 3, 2016 | Common Stock | 2,454,665 | 2,454,665 | D |
| WarrantsF3 | $0.0625 | Apr 3, 2015 | J | 6,726,999 | A | Oct 30, 2009 | Oct 30, 2016 | Common Stock | 6,726,999 | 15,349,042 | D |
| WarrantsF3 | $0.0625 | Apr 3, 2015 | J | 2,684,137 | A | Mar 31, 2011 | Mar 31, 2018 | Common Stock | 2,684,137 | 2,684,137 | D |
| WarrantsF3 | $0.0625 | Apr 3, 2015 | J | 4,000,000 | A | Apr 25, 2011 | Apr 25, 2018 | Common Stock | 4,000,000 | 4,000,000 | D |
Explanation of responses
- F1Disposition of warrants to its members
- F2Ashok Nigalaye is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI")(which is controlled by EP), which is a 10% owner of the issuer, and also serves as a director of the issuer.
- F3Ashok Nigalaye is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI") (which is controlled by EP), which is a 10% owner of the issuer, and also serves as a director of the issuer. Reporting person received these securities pursuant to a distribution by EI to members of Epic Pharma, LLC.